Arrowhead Pharmaceuticals, INC Form 4 insider transactions

Director Matthew Gregory Cohen received a grant of 11,882 restricted stock units from Arrowhead Pharmaceuticals.

Director Hongbo Lu sold 2,970 shares of Arrowhead Pharmaceuticals common stock at $76.88 per share.

Arrowhead Pharmaceuticals CFO Daniel Joseph Apel sold 13,095 shares of common stock to satisfy tax obligations via a 10b5-1 plan.

Arrowhead Pharmaceuticals Chief Medical Officer James C. Hamilton sold 10,000 shares of common stock via a 10b5-1 trading plan.

Arrowhead Pharmaceuticals' Chief Medical Officer, James C. Hamilton, was granted 75,000 restricted stock units vesting over four years.

Arrowhead Pharmaceuticals' Chief Financial Officer, Daniel Joseph Apel, was granted 75,000 restricted stock units, increasing his beneficial ownership to 176,200 shares.

Arrowhead Pharmaceuticals COO Patrick O'Brien reported gifting 2,500 shares of common stock and receiving a grant of 75,000 restricted stock units.

Arrowhead Pharmaceuticals COO Patrick O'Brien reported the disposition of common stock through gifts to relatives and sales under a 10b5-1 plan, including shares for tax withholding.

Arrowhead Pharmaceuticals' Chief Medical Officer, James C. Hamilton, filed a Form 4 detailing planned sales of 40,164 common shares in January 2026 under a 10b5-1 plan.

Arrowhead Pharmaceuticals CEO Christopher Anzalone sold 13,187 shares of common stock on January 2, 2026, to cover tax withholding obligations under a pre-arranged 10b5-1 plan.

Arrowhead Pharmaceuticals CEO Christopher Anzalone exercised and sold shares of common stock totaling 51,726 shares under a 10b5-1 trading plan.

Arrowhead Pharmaceuticals director Mauro Ferrari reported the sale of 7,530 common shares at $70 each, executed under a pre-arranged 10b5-1 trading plan.

Arrowhead Pharmaceuticals Director William D. Waddill sold 8,367 shares of common stock in planned transactions.

Arrowhead Pharmaceuticals Director Victoria Vakiener sold 10,040 shares of common stock on December 19, 2025, through a pre-arranged 10b5-1 trading plan.

Arrowhead Pharmaceuticals CEO Christopher Anzalone sold shares totaling 26,031 under a pre-arranged 10b5-1 trading plan in December 2025.

Arrowhead Pharmaceuticals Director Adeoye Y Olukotun sold 9,990 shares of common stock on December 19, 2025, through a pre-arranged 10b5-1 trading plan.

Arrowhead Pharmaceuticals CEO Christopher Anzalone sold shares of common stock on December 17, 2025, to cover tax obligations related to vested performance awards.

Arrowhead Pharmaceuticals Director Mauro Ferrari received a grant of 7,819 restricted stock units, aligning his interests with future company performance.

Arrowhead Pharmaceuticals Director Hongbo Lu was granted 7,819 restricted stock units, vesting in one year, increasing his direct beneficial ownership to 54,982 shares.

Arrowhead Pharmaceuticals director Michael Perry was granted 7,819 shares of common stock as restricted stock units, vesting in one year.

Arrowhead Pharmaceuticals Director Victoria Vakiener was granted 7,819 restricted stock units, vesting in December 2026.

Arrowhead Pharmaceuticals Director Douglas S. Ingram acquired 7,819 shares of common stock through a restricted stock unit grant.

Arrowhead Pharmaceuticals Director Adeoye Y. Olukotun was granted 7,819 restricted stock units, increasing his direct beneficial ownership to 43,600 shares.

Arrowhead Pharmaceuticals Director William D. Waddill was granted 7,819 restricted stock units, increasing his beneficial ownership to 64,930 shares.

Arrowhead Pharmaceuticals CEO Christopher Anzalone reported the vesting of 180,000 restricted stock units and subsequent sales of 184,298 shares to cover tax obligations.

Arrowhead Pharmaceuticals Director Michael S. Perry sold 16,250 shares of common stock for a weighted average price of $61.03, executed under a Rule 10b5-1 plan.

Arrowhead Pharmaceuticals director Mauro Ferrari sold 8,750 shares of common stock for $56.39 per share on November 28, 2025, under a pre-arranged trading plan.

James C. Hamilton, Chief Medical Officer of Arrowhead Pharmaceuticals, sold 20,000 shares of common stock for a weighted average price of $35.00 per share, totaling $700,000, pursuant to a pre-arranged 10b5-1 trading plan.

Arrowhead Pharmaceuticals' Chief Medical Officer, James C. Hamilton, sold 15,000 shares of common stock for $30 per share on September 12, 2025, under a pre-arranged 10b5-1 trading plan.

Arrowhead Pharmaceuticals' Chief Medical Officer, James C. Hamilton, sold 15,000 shares of common stock at $25 per share through a pre-arranged 10b5-1 trading plan.